http://aezsinc.com/portfolio/r-d-programs
Corporate Profile
Æterna Zentaris Inc. (TSX: AEZ, NASDAQ: AEZS) is a late-stage oncology drug development company currently investigating potential treatments for various cancers including colorectal, multiple myeloma, endometrial, ovarian, prostate and bladder cancer.The Company's innovative approach of "personalized medicine" means tailoring treatments to a patient's specific condition and to unmet medical needs. Aeterna Zentaris' deep pipeline is drawn from its proprietary discovery unit providing the Company with constant and long-term access to state-of-the-art therapeutic options.
http://www.aezsinc.com/en/index.php
News:
Yahoo feed:
http://finance.yahoo.com/q?s=aezs&ql=1
iHub feed:
http://ih.advfn.com/p.php?pid=news&symbol=N%5EAEZS
Contact us:
Canada
Norton Rose Fulbright Canada, LLP
1 Place Marie, Suite 2500
Montreal (Quebec), H3B 1R1
Canada
USA
Aeterna Zentaris, Inc.
315 Sigma Drive, Suite 302D
Summerville, SC 29483
Phone: (843) 900-3223
Germany
Aeterna Zentaris GmbH
Weismüllerstrasse 50
60314 Frankfurt
Germany
Phone: +49 69 42602 3228
Investor Fact Sheet: (March, 2017)
http://ir.aezsinc.com/sites/aezsinc.investorhq.businesswire.com/files/doc_library/file/Fact_sheet_MASTER_March_2017.pdf
Website:
http://aezsinc.com/
Clinical Trials:
http://clinicaltrials.gov/ct2/results?term=AEZS&Search=Search
Company Overview (February, 2107):
http://ir.aezsinc.com/sites/aezsinc.investorhq.businesswire.com/files/doc_library/file/Company_Overview_February_2017.pdf
Charts:
Gallery views:
http://stockcharts.com/freecharts/gallery.html?aezs
Daily three months:
